Use of anticoagulant therapy and cerebral microbleeds: a systematic review and meta-analysis
- 222 Downloads
Anticoagulant therapy increases the risk that cerebral microbleeds (CMBs) progress to intracerebral hemorrhage, but whether the therapy increases risk of CMB occurrence is unclear. We performed a systematic review and meta-analysis to investigate the potential association between anticoagulant use and CMB occurrence in stroke and stroke-free individuals.
We searched observational studies in PubMed, Ovid EMBASE, and Cochrane Library from their inception until September 2019. We calculated the pooled odds ratio (OR) and 95% confidence interval (CI) for the prevalence and incidence of CMBs in anticoagulant users relative to non-anticoagulant users.
Forty-seven studies with 25,245 participants were included. The pooled analysis showed that anticoagulant use was associated with CMB prevalence (OR 1.54, 95% CI 1.26–1.88). The association was observed in subgroups stratified by type of participants: stroke-free, OR 1.86, 95% CI 1.25–2.77; ischemic stroke/transient ischemic attack, OR 1.33, 95% CI 1.06–1.67; and intracerebral hemorrhage, OR 2.26, 95% CI 1.06–4.83. Anticoagulant use was associated with increased prevalence of strictly lobar CMBs (OR 1.68, 95% CI 1.22–2.32) but not deep/infratentorial CMBs. Warfarin was associated with increased CMB prevalence (OR 1.64, 95% CI 1.23–2.18), but novel oral anticoagulants were not. Anticoagulant users showed higher incidence of CMBs during long-term follow-up (OR 1.72, 95% CI 1.22–2.44).
Anticoagulant use is associated with higher prevalence and incidence of CMBs. This association appears to depend on location of CMBs and type of anticoagulants. More longitudinal investigations with adjustment for confounders are required to establish the causality.
KeywordsAnticoagulants Cerebral microbleeds Intracerebral hemorrhage Prevalence Incidence Meta-analysis
This study was supported by the National Key Research and Development Program, Ministry of Science and Technology of China (2016YFC1300500-505); Major International (Regional) Joint Research Project, National Natural Science Foundation of China (81620108009); Key Research and Development Program, Science &Technology Department of Sichuan Province (2017SZ0007); and the 1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYGD18009).
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
The manuscript does not contain clinical studies or patient data.
- 5.Wilson D, Ambler G, Shakeshaft C et al (2018) Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. Lancet Neurol 17:539–547PubMedPubMedCentralCrossRefGoogle Scholar
- 17.Rostom A, Dube C, Cranney A et al (2004) Celiac disease. Rockville (MD): Agency for Healthcare Research and Quality (US); (Evidence Reports/Technology Assessments, No. 104.) Appendix D. Quality Assessment Forms. https://www.ncbi.nlm.nih.gov/books/NBK35156. Accessed 11 Nov 2018
- 65.Yokoyama M, Mizuma A, Terao T et al (2019) Effectiveness of nonvitamin K antagonist oral anticoagulants and warfarin for preventing further cerebral microbleeds in acute ischemic stroke patients with nonvalvular atrial fibrillation and at least one microbleed: CMB-NOW multisite pilot trial. J Stroke Cerebrovasc Dis 28:1918–1925PubMedCrossRefPubMedCentralGoogle Scholar